Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velzatinib vs imatinib in first-line metastatic/unresectable GIST
2025-524934-24-00Phase 3Authorised
- Sponsor
- GSK
- Start
- Sep 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 27
01
Overview
Phase 3, randomised, open-label trial of IDRX-42 in gastrointestinal stromal tumor (GIST) (2 arms), sponsored by GSK. Primary endpoint: Progression-free survival (PFS) by BICR. Planned start Sep 2026; status: authorised.
02
Drugs
IDRX-42
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2025-524934-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524934-24-00.